EP 4200297 A1 20230628 - IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS
Title (en)
IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS
Title (de)
IMIDAZO[1,2-A PYRIDIN- UND [1,2,4 TRIAZOLO[1,5-A PYRIDIN-DERIVATE ALS TLR9 INHIBITOREN ZUR BEHANDLUNG VON FIBROSE
Title (fr)
DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINE ET DE [1,2,4]TRIAZOLO[1,5-A]PYRIDINE UTILES EN TANT QU'INHIBITEURS DE TLR9 POUR LE TRAITEMENT D'UNE FIBROSE
Publication
Application
Priority
- US 202063067452 P 20200819
- US 2021046420 W 20210818
Abstract (en)
[origin: WO2022040259A1] The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).
IPC 8 full level
C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61P 1/16 (2006.01); A61P 1/18 (2006.01); A61P 11/00 (2006.01); A61P 13/12 (2006.01); C07D 451/02 (2006.01); C07D 451/04 (2006.01)
CPC (source: EP IL KR US)
A61K 31/4545 (2013.01 - KR); A61P 1/16 (2018.01 - EP IL KR); A61P 1/18 (2018.01 - EP IL KR); A61P 11/00 (2018.01 - EP IL KR); A61P 13/12 (2018.01 - EP IL KR); C07D 451/02 (2013.01 - EP IL KR); C07D 451/04 (2013.01 - EP IL KR); C07D 471/04 (2013.01 - EP IL KR US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022040259 A1 20220224; AR 123281 A1 20221116; AU 2021328575 A1 20230316; BR 112023002737 A2 20230314; CA 3190065 A1 20220224; CN 116096717 A 20230509; EP 4200297 A1 20230628; IL 300727 A 20230401; JP 2023538393 A 20230907; KR 20230053644 A 20230421; MX 2023001885 A 20230310; TW 202227432 A 20220716; US 2024067638 A1 20240229
DOCDB simple family (application)
US 2021046420 W 20210818; AR P210102325 A 20210818; AU 2021328575 A 20210818; BR 112023002737 A 20210818; CA 3190065 A 20210818; CN 202180055737 A 20210818; EP 21766786 A 20210818; IL 30072723 A 20230215; JP 2023512226 A 20210818; KR 20237009016 A 20210818; MX 2023001885 A 20210818; TW 110130427 A 20210818; US 202118042036 A 20210818